Primary biliary cirrhosis secondary prevention
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dildar Hussain, MBBS [2]
Overview
Effective measures for the secondary prevention of primary biliary cirrhosis include follow up with liver function tests, thyroid status, upper GI endoscopy, bone mineral density, fat-soluble vitamin levels, ultrasound and alpha-fetoprotein levels to screen for hepatocellular carcinoma among aged men and patients with underlying cirrhosis.
Secondary Prevention
- Effective measures for the secondary prevention of primary biliary cirrhosis include:[1][2][3][4]
- Follow up with liver function tests every 3 to 6 months.
- Follow up with thyroid status annually.
- Follow up with upper GI endoscopy to assess for development of varices every 2-3 years.
- Follow up with bone mineral density every 2-4 years, depending upon the baseline density and severity of cholestasis.
- Follow up with fat-soluble vitamin levels (Vitamin A,D&K) annually in patients with bilirubin >2mg/dl.
- Follow up with ultrasound and alpha-fetoprotein levels to screen for hepatocellular carcinoma every 6 to 12 months among aged men and patients with underlying cirrhosis.
References
- ↑ Chazouillères O, Wendum D, Serfaty L, Rosmorduc O, Poupon R (2006). “Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome”. J. Hepatol. 44 (2): 400–6. doi:10.1016/j.jhep.2005.10.017. PMID 16356577.
- ↑ Poupon, Raoul; Chazouilleres, Olivier; Corpechot, Christophe; Chrétien, Yves (2006). “Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis”. Hepatology. 44 (1): 85–90. doi:10.1002/hep.21229. ISSN 0270-9139.
- ↑ Colombato LA, Alvarez F, Côté J, Huet PM (1994). “Autoimmune cholangiopathy: the result of consecutive primary biliary cirrhosis and autoimmune hepatitis?”. Gastroenterology. 107 (6): 1839–43. PMID 7958699.
- ↑ Weyman RL, Voigt M (2001). “Consecutive occurrence of primary biliary cirrhosis and autoimmune hepatitis: a case report and review of the literature”. Am. J. Gastroenterol. 96 (2): 585–7. doi:10.1111/j.1572-0241.2001.03562.x. PMID 11232713.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH